Multibagger Selection: Grok 4.5's picks
Grok 4.5 picked NRIX, INOD, LQDA, CELC, APLD with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | Grok 4.5 |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | NRIX | — | 75% | — | — |
| 2 | INOD | — | 70% | — | — |
| 3 | LQDA | — | 68% | — | — |
| 4 | CELC | — | 55% | — | — |
| 5 | APLD | — | 52% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | +2.33% | +1.45% | 1.19x | 0 |
The model's market view
Small and mid-cap growth names in biotech (degraders, commercial specialty pharma) and AI data services show the strongest evidence of operating inflection and specific near-term catalysts within the 200M-5B market-cap window. Liquidity and volume screens are met by the selected names; broader market remains selective with preference for clear commercial or late-stage clinical de-risking.
Why each pick
NRIX
Nurix has transitioned to a well-funded platform company via the Roche collaboration on bexobrutideg (BTK degrader). Phase 3 DAYBreak CLL-306 is underway; multiple additional pipeline readouts and partner milestones are scheduled through 2027. Cash runway into 2H 2029 removes near-term dilution pressure while revenue has already inflected sharply from collaboration payments.
INOD
Innodata provides high-value AI training, evaluation and observability data services. Revenue growth has accelerated above 50% with expanding gross margins and new large tech customers reducing concentration. Continued AI model demand and agentic/physical AI work provide multi-year runway.
LQDA
Liquidia commercializes YUTREPIA (inhaled treprostinil) for PAH and is expanding into PH-ILD. Global settlement with United Therapeutics removed the major litigation overhang, enabling uninterrupted sales growth and pipeline advancement funded by operating cash flow.
CELC
Celcuity is advancing gedatolisib in breast cancer with late-stage data expected. Recent initiation of coverage and pipeline progress provide catalyst visibility inside the market-cap window.
APLD
Applied Digital is expanding high-performance computing and AI data-center capacity. Recent reinstatement of coverage and capacity ramps provide visibility into revenue acceleration.
Other models on the same run
| Model | Picks |
|---|---|
| Claude Opus 5.5 | URGN, AXTI, ETON, INOD, BKSY |
| Gemini 3 Pro | BHVN, SG, SMR, JOBY, RDW |
| Muse Spark 1.1 | KOD, CAPR, IVA, RCUS, TPC |
| DeepSeek | INOD, ONDS, SVRA, AQST, INBX |
| GPT-6 | AMPX, BKSY, RCAT, ENVX, OUST |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.